Company: INDP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001641172-25-023499
Chunk: 28

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 28
---
 subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents.

We will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any or all documents that are incorporated by reference into this prospectus, but not delivered with the prospectus, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates. You should direct oral or written requests by one of the following methods. Attention: Investor Relations, Indaptus Therapeutics, Inc., Three Columbus Circle, 15th Floor New York, NY 10019, (646) 427-2727. You may also access these documents, free of charge on the SEC’s website at www.sec.gov or on the “Investors” page of our website at https://indaptusrx.com. The information found on our website, or that may be accessed by links on our website, is not part of this prospectus. We have included our website address solely as an inactive textual reference. Investors should not rely on any such information in deciding whether to purchase our common stock.

| 23 |

<div align='center'>PART II

INFORMATION NOT REQUIRED IN PROSPECTUS</div>

Item 14. Other Expenses of Issuance and Distribution.

The following is an estimate of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securities being registered hereby, other than the Securities and Exchange Commission registration fee:

| SEC Registration Fee         |     | $ |  2,329 |
| Accounting Fees and Expenses |     |   |  7,500 |
| Legal Fees and Expenses      |     |   | 15,000 |
| Printing Fees and Expenses   |     |   |  2,500 |
| Total                        |     | $ | 27,329 |

Item 15. Indemnification of Directors and Officers.

Section 145 of the Delaware General Corporation Law provides that